Initial data from the ongoing OCTAVE study shows that a significant proportion of clinically at-risk patients with certain immunocompromised or immunosuppressed conditions, mount a low, or undetectable, immune response after two doses of the same COVID-19 vaccine. The OCTAVE study – a multi-centre, UK-wide trial, led by the University of Glasgow and co-ordinated by the […]